Novel compound enables high-level adenovirus transduction in the absence of an adenovirus-specific receptor

Human Gene Therapy

Volumn 16, Issue 11, 2005, Pages 1287-1297

  Fouletier Dilling, Christine M ^a   Bosch, Pablo ^b   Davis, Alan R ^a,c   Shafer, Jessica A ^a,c   Stice, Steven L ^b   Gugala, Zbigniew ^c   Gannon, Francis H ^d   Olmsted Davis, Elizabeth A ^a,c  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN 2; CAPSID PROTEIN; ENHANCED GREEN FLUORESCENT PROTEIN; POLYAMINE; VIRUS RECEPTOR;

ANIMAL CELL; ARTICLE; CARCINOMA CELL; CELL BASED GENE THERAPY; CELL SPECIFICITY; CHO CELL; CONTROLLED STUDY; DNA TRANSFECTION; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE TARGETING; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNOCOMPETENCE; MESENCHYME CELL; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; CELLS, CULTURED; CHO CELLS; CRICETINAE; FLOW CYTOMETRY; HUMANS; MICE; RECEPTORS, VIRUS; TRANSDUCTION, GENETIC;

ADENOVIRIDAE; ANIMALIA; MIRIDAE;

EID: 27744523702     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2005.16.1287     Document Type: Article

References (30)

1. BALAKIREVA, L., SCHOEHN, G., THOUVENIN, E., and CHROBOCZEK, J. (2003). Binding of adenovirus capsid to dipalmitoyl phosphatidylcholine provides a novel pathway for virus entry. J. Virol. 77, 4858-1866.
2. BERGELSON, J.M., CUNNINGHAM, J.A., DROGUETT, G., KURT-JONES, E.A., KRITHIVAS, A., HONG, J.S., HORWITZ, M.S., CROWELL, R.L., and FINBERG, R.W. (1997). Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 275, 1320-1323.
3. BLUM, J.S., LI, R.H., MIKOS, A.G., and BARRY, M.A. (2001). An optimized method for the chemiluminescent detection of alkaline phosphatase levels during osteodifferentiation by bone morphogenetic protein 2. J. Cell. Biochem. 80, 532-537.
4. BONADIO, J., SMILEY, E., PATIL, P., and GOLDSTEIN, S. (1999). Localized, direct plasmid gene delivery in vivo: Prolonged therapy results in reproducible tissue regeneration. Nat. Med. 5, 753-759.
5. BYK, T., HADDADA, H., VAINCHENKER, W., and LOUACHE, F. (1998). Lipofectamine and related cationic lipids strongly improve adenoviral infection efficiency of primitive human hematopoietic cells. Hum. Gene Ther. 9, 2493-2502.
6. DAVISON, E., KIRBY, I., ELLIOTT, T., and SANTIS, G. (1999). The human HLA-A*0201 allele, expressed in hamster cells, is not a high-affinity receptor for adenovirus type 5 fiber. J. Virol. 73, 4513-1517.
7. FRANCESCHI, R.T., YANG, S., RUTHERFORD, R.B., KREBSBACH, P.H., ZHAO, M., and WANG, D. (2004). Gene therapy approaches for bone regeneration. Cells Tissues Organs 176, 95-108.
8. GAGGAR, A., SHAYAKHMETOV, D.M., and LIEBER, A. (2003). CD46 is a cellular receptor for group B adenoviruses. Nat. Med. 9, 1408-1412.
9. GAO, W., ROBBINS, P.D., and GAMBOTTO, A. (2003). Human adenovirus type 35: Nucleotide sequence and vector development. Gene Ther. 10, 1941-1949.
10. GUGALA, Z., OLMSTED-DAVIS, E.A., CANNON, F.H., LINDSEY, R.W., and DAVIS, A.R. (2003). Osteoinduction by ex vivo adenovirus-mediated BMP2 delivery is independent of cell type. Gene Ther. 10, 1289-1296.
11. + hematopoietic cells. Biotechniques 19, 816-823.
12. HIDAKA, C., MILANO, E., LEOPOLD, P.L., BERGELSON, J.M., HACKETT, N.R., FINBERG, R.W., WICKHAM, T.J., KOVESDI, I., ROELVINK, P., and CRYSTAL, R.G. (1999). CAR-dependent and CAR-independent pathways of adenovirus vector-mediated gene transfer and expression in human fibroblasts. J. Clin. Invest. 103, 579-587.
13. JAISWAL, N., HAYNESWORTH, S.E., CAPLAN, A.I., and BRUDER, S.P. (1997). Osteogenic differentiation of purified, culture-expanded human mesenchymal stem cells in vitro. J. Cell. Biochem. 64, 295-312.
14. KIM, H.S., VIGGESWARAPU, M., BODEN, S.D., LIU, Y., HAIR, G.A., LOUIS-UGBO, J., MURAKAMI, H., MINAMIDE, A., SUH, D.Y., and TITUS, L. (2003). Overcoming the immune response to permit ex vivo gene therapy for spine fusion with human type 5 adenoviral delivery of the LIM mineralization protein-1 cDNA. Spine 28, 219-226.
15. LANUTI, M., KOURI, C.E., FORCE, S., CHANG, M., AMIN, K., XU, K., BLAIR, I., KAISER, L., and ALBELDA, S. (1999). Use of protamine to augment adenovirus-mediated cancer gene therapy. Gene Ther. 6, 1600-1610.
16. MALLAM, J.N., HURWITZ, M.Y., MAHONEY, T., CHEVEZ-BARRIOS, P., and HURWITZ, R.L. (2004). Efficient gene transfer into retinal cells using adenoviral vectors: Dependence on receptor expression. Invest. Ophthalmol. Vis. Sci. 45, 1680-1687.
17. MARIT, G., CAO, Y., FROUSSARD, P., RIPOCHE, I., DUPOUY, M., ELANDALOUSSI, A., LACOMBE, F., MAHON, F.X., KELLER, H., PLA, M., REIFFERS, I., and THEZE, I. (2000). Increased liposome-mediated gene transfer into haematopoietic cells grown in adhesion to stromal or fibroblast cell line monolayers. Eur. J. Haematol. 64, 22-31.
18. MIZUGUCHI, H., and HAYAKAWA, T. (2002). Adenovirus vectors containing chimeric type 5 and type 35 fiber proteins exhibit altered and expanded tropism and increase the size limit of foreign genes. Gene 285, 69-77.
19. MUSGRAVE, D.S., BOSCH, P., LEE, J.Y., PELINKOVIC, D., GHIVIZZANI, S.C., WHALEN, J., NIYIBIZI, C., and HUARD, J. (2000). Ex vivo gene therapy to produce bone using different cell types. Clin. Orthop. Relat. Res. 378, 290-305.
20. OLMSTED, E.A., BLUM, J.S., RILL, D., YOTNDA, P., GUGALA, Z., LINDSEY, R.W., and DAVIS, A.R. (2001). Adenovirus-mediated BMP2 expression in human bone marrow stromal cells. J. Cell. Biochem. 82, 11-21.
21. OLMSTED-DAVIS, E.A., GUGALA, Z., CANNON, F.H., YOTNDA, P., MCALHANY, R.E., LINDSEY, R.W., and DAVIS, A.R. (2002). Use of a chimeric adenovirus vector enhances BMP2 production and bone formation. Hum. Gene Ther. 13, 1337-1347.
22. PARK, J., RIES, J., GELSE, K., KLOSS, F., VON DER MARK, K., WILTFANG, J., NEUKAM, F.W., and SCHNEIDER, H. (2003). Bone regeneration in critical size defects by cell-mediated BMP-2 gene transfer: A comparison of adenoviral vectors and liposomes. Gene Ther. 10, 1089-1098.
23. + cells by an adenovirus type 35 vector. Gene Ther. 10, 1041-1048.
24. SEGERMAN, A., ATKINSON, J.P., MARTTILA, M., DENNERQUIST, V., WADELL, G., and ARNBERG, N. (2003). Adenovirus type 11 uses CD46 as a cellular receptor. J. Virol. 77, 9183-9191.
25. THIES, R.S., BAUDUY, M., ASHTON, B.A., KURTZBERG, L., WOZNEY, J.M., and ROSEN, V. (1992). Recombinant human bone morphogenetic protein-2 induces osteoblastic differentiation in W-20-17 stromal cells. Endocrinology 130, 1318-1324.
26. TOYODA, K., NAKANE, H., and HEISTAD, D.D. (2001). Cationic polymer and lipids augment adenovirus-mediated gene transfer to cerebral arteries in vivo. J. Cereb. Blood Flow Metab. 21, 1125-1131.
27. TSUDA, H., WADA, T., ITO, Y., UCHIDA, H., DEHARI, H., NAKAMURA, K., SASAKI, K., KOBUNE, M., YAMASHITA, T., and HAMADA, H. (2003). Efficient BMP2 gene transfer and bone formation of mesenchymal stem cells by a fiber-mutant adenoviral vector. Mol. Ther. 7, 354-365.
28. TURGEMAN, G., ZILBERMAN, Y., ZHOU, S., KELLY, P., MOUTSATSOS, I.K., KHARODE, Y.P., BORELLA, L.E., BEX, F.J., KOMM, B.S., BODINE, P.V., and GAZIT, D. (2002). Systemically administered rhBMP-2 promotes MSC activity and reverses bone and cartilage loss in osteopenic mice. J. Cell. Biochem. 86, 461-174.
29. YOTNDA, P., CHEN, D.H., CHIU, W., PIEDRA, P.A., DAVIS, A., TEMPLETON, N.S., and BRENNER, M.K. (2002). Bilamellar cationic liposomes protect adenovectors from preexisting humoral immune responses. Mol. Ther. 5, 233-241.
30. ZHU, W., RAWLINS, B.A., BOACHIE-ADJEI, O., MYERS, E.R., ARIMIZU, J., CHOI, E., LIEBERMAN, J.R., CRYSTAL, R.G., and HIDAKA, C. (2004). Combined bone morphogenetic protein-2 and -7 gene transfer enhances osteoblastic differentiation and spine fusion in a rodent model. J. Bone Miner. Res. 19, 2021-2032.